

Special Issue

Antimicrobial Stewardship Program (ASP) in General Hospital: An Essential Practice

Message from the Guest Editor

Antimicrobial drugs are unique in that through the development of resistance, any misuse might affect not only the patients who receive them but future patients as well. Thus, when we prescribe an antimicrobial course, we should be thinking in a context broader than the patient before us. Although the bulk of antimicrobial prescribing occurs in the community, it is in the hospital where one faces the consequences of antimicrobial drug misuse, i.e., multi-drug resistant pathogens. In addition, hospitals are the settings where new antimicrobials are mostly used. This Special Issue aims to highlight the challenges that the Antimicrobial Stewardship Program (ASP) of General Hospitals must tackle, such as selection of empirical antimicrobial therapy in settings of endemic multi-drug resistant pathogens, management of perioperative prophylaxis, use of antifungal drugs, use of novel laboratory techniques, and management of resources, especially during the COVID-19 pandemic. We invite you to submit original research articles, reviews, or meta-analyses, related but not limited to the above challenges that the ASP of a General Hospital must address.

Guest Editor

Dr. Michael Samarkos

1st Department of Internal Medicine & Infectious Diseases Unit, General Hospital of Athens Laikon, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

Deadline for manuscript submissions

closed (15 July 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/134017

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)